The AI-Driven Precision Medicine (AID-PM) initiative aims to position Sweden nationally and internationally as a leading actor in precision medicine. Through close collaboration between academia, industry and healthcare, new AI-based solutions will be developed to improve diagnostics, treatments and drug development.

AI is paving the way for tailored healthcare

Just as tailored clothing is adapted to an individual’s unique measurements, treatments in precision medicine are tailored based on patients’ specific genetic and health-related conditions.

AI enables opportunities to analyse extensive genetic datasets, lifestyle data and medical images to develop treatments that are more precise, effective and gentle, and replacing standardised methods with personalised therapies.

Sweden as a leader in AI-driven precision medicine

The AI-Driven Precision Medicine (AID-PM) initiative aims to establish Sweden as a national and international leader in precision medicine. Through close collaboration between academia, industry and healthcare, new AI-driven solutions will be developed to improve diagnostics, treatments and drug development.

Four focus areas with groundbreaking potential

The focus is on four key areas:

• digital diagnostics, where AI methods enable faster and more reliable disease identification;
• repurposing of approved drugs for new therapeutic use;
• development of 3D biomodels that mimic human tissues to enhance understanding of diseases and treatments; and
• advanced therapeutic medicinal products (ATMPs), such as cell and gene therapies as well as tissue transplants.

AI that understands – and explains – to support clinical care

This initiative integrates several AI methods, including neural networks and generative models, to analyse complex and high-dimensional data, such as medical images and sequencing data over time.

Special emphasis is placed on developing explainable AI models, allowing physicians to understand and trust the model’s decisions, which is crucial for widespread clinical adoption.

During the first four years, significant volumes of high-quality data will be generated alongside with development of advanced AI models targeting specific medical challenges.

Shared digital platform enabling global collaboration

A shared digital platform will be developed to support physicians and healthcare professionals with clear and adaptable decision support. The platform will enable international collaboration for large-scale validation of results, thereby enhancing the reliability and clinical relevance of the AI models.

Building expertise and driving sustainable innovation

The initiative also includes a strong educational component aimed at fostering the next generation of experts in AI and precision medicine.

By integrating research, education and industrial collaboration, AID-PM contributes to strengthening Sweden’s life science sector and enables new innovations with significant potential to improve the lives of patients globally.

AID-PM tackles critical challenges related to data integration, ethics and patient privacy, and strives to develop sustainable and cost-effective therapies.

The initiative plays a pivotal role in the global development of precision medicine, where AI and industry collaboration unlock new possibilities for personalised, effective healthcare.